Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Factors Affecting the Risk of Infection01:26

Factors Affecting the Risk of Infection

14.5K
The hosts' susceptibility to infection depends on several factors. The integrity of the skin and mucous membranes helps protect the body against microbial attacks. When the skin is altered, the chance of infection, limb loss, and even death increases.
The integrity and count of the white blood cells help the body resist pathogens and fight infection. When impaired, it reduces the body's resistance to pathogens. The acidic pH levels of the gastrointestinal, genitourinary tracts, and skin...
14.5K
Healthcare Associated Infections I: Iatrogenic, Exogenic and Endogenic01:26

Healthcare Associated Infections I: Iatrogenic, Exogenic and Endogenic

6.4K
Healthcare-associated infections (HAIs) occur in a healthcare facility while a person receives care for another ailment. This category also includes work-related infections among healthcare staff.
HAIs significantly increase the cost of health care. Extended stays in healthcare institutions, increased disability, increased costs of medications, including specialized antibiotics, and prolonged recovery times add to the patient's expenses and the healthcare institution and funding bodies.
6.4K
Inflammatory Bowel Disease II: Crohn's Disease01:30

Inflammatory Bowel Disease II: Crohn's Disease

1.5K
Introduction
Inflammatory bowel disease, commonly known as IBD, refers to a collection of disorders that lead to persistent inflammation of the gastrointestinal tract. The two types of IBD are ulcerative colitis, which impacts the colon, and Crohn's disease, which can involve any part of the gastrointestinal segment.
Crohn's disease
Crohn's disease is a chronic, systemic inflammatory bowel disease (IBD) that predominantly affects the gastrointestinal tract. It is marked by...
1.5K
Urinary Tract Infection II: Pathophysiology01:25

Urinary Tract Infection II: Pathophysiology

1.0K
The pathophysiology of urinary tract infections (UTIs) encompasses several progressive stages, beginning with bacterial colonization and culminating in potential systemic complications if untreated. UTIs are primarily initiated by bacteria, such as Escherichia coli, which often originate from the gastrointestinal tract and migrate to the urinary system through the periurethral area. This migration can occur via several routes, including improper hygiene practices, sexual activity, or...
1.0K
Inflammatory Bowel Disease I: Ulcerative Colitis01:27

Inflammatory Bowel Disease I: Ulcerative Colitis

1.4K
Introduction
Inflammatory bowel disease, or IBD, encompasses a group of disorders characterized by chronic inflammation or ulceration of the gastrointestinal tract.
Risk Factors
The exact cause of IBD remains unclear, although it is believed to be due to a mix of genetic, environmental, microbial, and immune factors. Genetic factors are significant in determining susceptibility to IBD, with family history being a critical risk factor. Individuals with a first-degree relative who has IBD are at...
1.4K
Chronic Bowel Disorders: Introduction01:17

Chronic Bowel Disorders: Introduction

883
Chronic bowel diseases are a group of long-term conditions affecting the digestive tract, characterized by inflammation and damage to the gut lining. These conditions primarily include irritable bowel syndrome and inflammatory bowel disease.
Irritable Bowel Syndrome (IBS) is a common disorder affecting the gastrointestinal tract. The distinctive feature is recurrent abdominal pain associated with altered bowel movements, manifesting as constipation, diarrhea, or fluctuating between both. The...
883

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Argyrin B exhibits potent therapeutic efficacy in a Clostridioides difficile-infection mouse model while preserving microbiota functionality.

npj antimicrobials and resistance·2026
Same author

[Need for improvement in the care of patients with Clostridioides difficile infections (CDI) - expert opinion in international comparison].

Zeitschrift fur Gastroenterologie·2024
Same author

Multiplex PCR for bacterial, viral and protozoal pathogens in persistent diarrhoea or persistent abdominal pain in Côte d'Ivoire, Mali and Nepal.

Scientific reports·2024
Same author

Discrimination between hypervirulent and non-hypervirulent ribotypes of Clostridioides difficile by MALDI-TOF mass spectrometry and machine learning.

European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology·2023
Same author

[Fecal Microbiota Transfer (FMT) in Germany - Status and Perspective].

Zeitschrift fur Gastroenterologie·2023
Same author

Trends in the epidemiology of Clostridioides difficile infection in Germany.

Infection·2023

Related Experiment Video

Updated: Mar 16, 2026

Cefoperazone-treated Mouse Model of Clinically-relevant Clostridium difficile Strain R20291
06:51

Cefoperazone-treated Mouse Model of Clinically-relevant Clostridium difficile Strain R20291

Published on: December 10, 2016

13.4K

[New aspects on Clostridium difficile infection].

Lutz von Müller

    Deutsche Medizinische Wochenschrift (1946)
    |August 11, 2016
    PubMed
    Summary

    Fecal microbiota transplantation (FMT) and next-generation probiotics show promise for treating Clostridium difficile infection (CDI). Understanding the gut microbiome and host immunity is key to developing these novel microbiome-based therapies.

    Area of Science:

    • Microbiology
    • Immunology
    • Gastroenterology

    Background:

    • Clostridium difficile infection (CDI) is a complex disease influenced by bacterial virulence, host immunity, and the gut microbiome.
    • Current antibiotic treatments for CDI are often associated with adverse side effects.
    • Emerging research highlights the role of specific microorganisms in disease protection.

    Purpose of the Study:

    • To explore novel therapeutic strategies for Clostridium difficile infection.
    • To investigate the potential of microbiome-based interventions.
    • To underscore the importance of understanding host-microbiome interactions in CDI.

    Main Methods:

    • Review of current research on Clostridium difficile infection.
    • Analysis of the role of gut microbiota in CDI pathogenesis.

    More Related Videos

    A Protocol to Characterize the Morphological Changes of Clostridium difficile in Response to Antibiotic Treatment
    12:58

    A Protocol to Characterize the Morphological Changes of Clostridium difficile in Response to Antibiotic Treatment

    Published on: May 25, 2017

    9.5K
    A Protein Microarray Assay for Serological Determination of Antigen-specific Antibody Responses Following Clostridium difficile Infection
    09:12

    A Protein Microarray Assay for Serological Determination of Antigen-specific Antibody Responses Following Clostridium difficile Infection

    Published on: June 15, 2018

    10.5K

    Related Experiment Videos

    Last Updated: Mar 16, 2026

    Cefoperazone-treated Mouse Model of Clinically-relevant Clostridium difficile Strain R20291
    06:51

    Cefoperazone-treated Mouse Model of Clinically-relevant Clostridium difficile Strain R20291

    Published on: December 10, 2016

    13.4K
    A Protocol to Characterize the Morphological Changes of Clostridium difficile in Response to Antibiotic Treatment
    12:58

    A Protocol to Characterize the Morphological Changes of Clostridium difficile in Response to Antibiotic Treatment

    Published on: May 25, 2017

    9.5K
    A Protein Microarray Assay for Serological Determination of Antigen-specific Antibody Responses Following Clostridium difficile Infection
    09:12

    A Protein Microarray Assay for Serological Determination of Antigen-specific Antibody Responses Following Clostridium difficile Infection

    Published on: June 15, 2018

    10.5K
  • Evaluation of fecal microbiota transplantation (FMT) as a treatment option.
  • Exploration of bacteriotherapy with next-generation probiotics.

    • Main Results:

    • Fecal microbiota transplantation (FMT) is an emerging treatment for CDI.
    • Knowledge of protective microorganisms is expanding due to C. difficile research.
    • Next-generation probiotics may soon be applicable for treating various diseases.

    Conclusions:

    • The complex interplay between virulence factors, host immunity, and the microbiome offers therapeutic opportunities for CDI.
    • Fecal microbiota transplantation (FMT) represents a significant advancement in CDI treatment.
    • Further research into protective microorganisms may lead to new probiotic-based therapies for CDI and other conditions.
    • CDI serves as a critical reminder for the judicious use of antibiotics.